Update on the clinical use of buprenorphine: In opioid-related disorders;Mise à jour sur l'utilisation clinique de la buprénorphine: Pour les troubles reliés aux opioïdes

Canadian Family Physician

Volumn 58, Issue 1, 2012, Pages

  Ducharme, Simon ^a   Fraser, Ronald ^a   Gill, Kathryn ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; METHADONE; NORBUPRENORPHINE; PLACEBO;

ANALGESIA; CONSTIPATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG RETENTION; DRUG SAFETY; DRUG USE; GENERAL PRACTITIONER; HEADACHE; HUMAN; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); NAUSEA; OPIATE ADDICTION; PRESCRIPTION; PRIMARY MEDICAL CARE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; METABOLIC DETOXICATION, DRUG; OPIOID-RELATED DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 84856113815     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Fischer B, Firestone Cruz M, Rhem J. Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry 2006;51(10):624-34. (Pubitemid 44526424)
2. Remis R, Leclerc P, Routledge R, Taylor C, Bruneau J, Beauchemin J. Consortium to characterize injection drug users in Canada (Montreal, Toronto and Vancouver). Final report. Toronto, ON: University of Toronto; 1998.
3. Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach - the case study of Canada. J Urban Health 2004;81(3):428-47. (Pubitemid 39128279)
4. Zou S, Tepper M, Giulivi A. Current status of hepatitis C in Canada. Can J Public Health 2000;91(Suppl 1):S10-5.
5. Fischer B, Rehm J, Patra J, Firestone Cruz M. Changes in illicit opioid use across Canada. CMAJ 2006;175(11):1385-7. (Pubitemid 44876556)
6. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006;81(2):103-7. Epub 2005 Jul 14.
7. Nace EP, Davis CW, Gaspari JP. Axis II comorbidity in substances abusers. Am J Psychiatry 1991;148(1):118-20.
8. Krausz M, Degkwitz P, Kühne A, Verthein U. Comorbidity of opiate dependence and mental disorders. Addict Behav 1998;23(6):767-83. (Pubitemid 28443191)
9. Van Den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry 2006;51(10):635-46. (Pubitemid 44526425)
10. Knudsen HJ, Abraham AJ, Johnson JA, Roman PM. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat 2009;37(3):307-12. Epub 2009 Jul 3.
11. Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend 2010;106(1):56-60. Epub 2009 Aug 29.
12. Fiellin DA, Kleber H, Trumble-Hejduk J, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004;27(2):153-9. (Pubitemid 39265427)
13. Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med 2007;1(2):62-7.
14. Gwin Mitchell S, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhf A, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict 2009;18(5):346-55.
15. Bezchlibnyk-Butler KZ, Jeffries J, Virani A. Clinical handbook of psychotropic drugs. 17th ed. Cambridge, MA: Hogrefe & Huber Publishers; 2007.
16. Mello NK, Mendelson JH. Behavioral pharmacology of buprenorphine. Drug Alcohol Depend 1985;14(3-4):283-303. (Pubitemid 15149052)
17. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55(5):569-80. (Pubitemid 24192243)
18. Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004;2(4):395-402. (Pubitemid 39276631)
19. Strain EC, Preston KL, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effect at two hours after methadone. J Pharmacol Exp Ther 1995;272(2):628-38.
20. Blom Y, Bondesson U, Gunne LM. Effects of buprenorphine in heroin addicts. Drug Alcohol Depend 1987;20(1):1-7.
21. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35(4):501-16. (Pubitemid 8337042)
22. Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996;20(6):369-78. (Pubitemid 26327458)
23. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005;44(7):661-80. (Pubitemid 40994078)
24. Schuh KJ, Walsh SL, Stitzer ML. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology (Berl) 1999;145(2):162-74. (Pubitemid 29362014)
25. San L, Cami J, Fernàndez T, Ollé JM, Peri JM, Torrens M. Assessment and management of opioid withdrawal symptoms in buprenorphine- dependent subjects. Br J Addict 1992;87(1):55-62.
26. O'Connor JJ, Moloney E, Travers R, Campbell A. Buprenorphine abuse among opiate addicts. Br J Addict 1988;83(9):1085-7.
27. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003;70(2 Suppl):S39-47. (Pubitemid 36556059)
28. Bigelow GE, Preston KL, Liebson IA. Abuse liability assessment of buprenorphinenaloxone combinations. NIDA Res Monogr 1987;76:145-9.
29. Weinhold LL, Preston KL, Farre M, Liebson IA, Bigelow GE. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend 1992;30(3):263-74.
30. Preston KL, Bigelow GE, Liebson I. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 1988;94(4):484-90. (Pubitemid 18087397)
31. Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1990;26(1):19-28. (Pubitemid 20254839)
32. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998;93(9):1385-92. (Pubitemid 28430045)
33. Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167(22):2469-75. (Pubitemid 350254906)
34. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009;104(6):993-9. Epub 2009 Apr 9.
35. Farrell M. Opiate withdrawal. Addiction 1994;89(11):1471-5. (Pubitemid 24343907)
36. Gossop M, Bradley B, Phillips G. An investigation of withdrawal symptoms shown by opiate addicts during and subsequent to a 21-day in-patient methadone detoxification procedure. Addict Behav 1987;12(1):1-6. (Pubitemid 17000635)
37. Kleber H. Detoxification from narcotics. In: Lowinson JH, Ruiz P, editors. Substance abuse: clinical issues and perspectives. Baltimore, MD: Williams and Wilkins; 1981.
38. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009;(3):CD002025.
39. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006;(2):CD002025.
40. Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, et al. A multicenter randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005;100(8):1090-100. Erratum in: Addiction 2006;101(9):1374. (Pubitemid 41113602)
41. Wang R, Young L. Double-blind controlled detoxification from buprenorphine. NIDA Res Monogr 1996;162:114.
42. Pycha C, Resnick R, Galanter M. Buprenorphine: rapid and slow dose-reduction for heroin detoxification. NIDA Res Monogr 1994;141:453.
43. Amass L, Bickel WK, Higgins ST, Hughes JR. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis 1994;13(3):33-45.
44. Ling W, Hillhouse M, Dornier C, Doraimani G, Hunter J, Thomas C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009;104(2):256-65.
45. Katz EC, Schwartz RP, King S, Highfield DA, O'Grady KE, Billings T, et al. Brief vs. extended buprenorphine detoxification in a community treatment program: engagement and short-term outcomes. Am J Drug Alcohol Abuse 2009;35(2):63-7.
46. Schering-Plough Canada. Suboxone product monograph. Kirkland, QC: Schering- Plough Canada; 2007.
47. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
48. Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and singleitem indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend 2009;105(1-2):154-9. Epub 2009 Aug 3.
49. Knotkova H, Fine PJ, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage 2009;38(3):426-39.
50. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;(2):CD002207.
51. Isaac P, Janecek E, Kavlik A, Sproule B. Buprenorphine: a new treatment for opioid dependence. Pharm Connection 2008;Feb:32-7.
52. Sohler NL, Li X, Kunins H, Sacajiu G, Giovanniello A, Whitley S, et al. Home- versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat 2010;38(2):153-9. Epub 2009 Oct 3.
53. Kahan M, Srivastava A, Ordean A, Cirone S. Buprenorphine. New treatment of opioid addiction in primary care. Can Fam Physician 2011;57:281-9. Available from: www.cfp.ca/content/57/3/281.full.pdf+html. Accessed 2011 Nov 21.
54. Gossop M, Green L, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry 1989;154:348-53. (Pubitemid 19091811)
55. Dole VP, Nyswander ME. Heroin addiction - a metabolic disease. Arch Intern Med 1967;120(1):19-24.
56. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 2003;361(9358):662-8. (Pubitemid 36246548)
57. Fudala PJ, Bridge T, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58. (Pubitemid 37064768)
58. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993;181(6):358-64. (Pubitemid 24259606)
59. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone in opioid dependence. Arch Gen Psychiatry 1996;53(5):401-7. (Pubitemid 26149228)
60. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994;151(7):1025-30. (Pubitemid 24208639)
61. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996;16(1):58-67.
62. West SL, O'Neal KK, Graham CW. A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 2000;12(4):405-14. (Pubitemid 38201228)
63. Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96(5):683-90. (Pubitemid 32458706)
64. Petitjean S, Stohler R, Déglon JJ, Livoti S, Waldvogel D, Uehlinger C, et al. Doubleblind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001;62(1):97-104. (Pubitemid 32149970)
65. Kakko J, Grönbladh L, Svanborg K, von Wachenfeldt J, Rück C, Rawlings B, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164(5):797-803. (Pubitemid 46808535)
66. Sullivan LE, Moore BA, Chawarski MC, Pantalon MV, Barry D, O'Connor PG, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat 2008;35(1):87-92. Epub 2007 Oct 15.
67. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1):113-6. (Pubitemid 41557130)
68. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O'Connor PG, et al. Counselling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355(4):365-74. (Pubitemid 44127539)
69. Dutra L, Stathopoulos G, Basden SL, Leyro TM, Powers MB, Otto MW. A metaanalytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165(2):179-87. Epub 2008 Jan 18.
70. Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter randomized clinical trial. Addiction 1998;93(4):475-86. (Pubitemid 28188067)
71. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 2003;24(3):217-20. (Pubitemid 37297338)
72. Schottenfeld RS, Pakes J, O'Connor P, Chawarski M, Oliveto A, Kosten TR. Thriceweekly versus daily buprenorphine maintenance. Biol Psychiatry 2000;47(12):1072-9. (Pubitemid 30336216)
73. Pérez de los Cobos J, Martin S, Etcheberrigaray A, Trujols J, Batlle F, Tejero A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend 2000;59(3):223-33. (Pubitemid 30254238)
74. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999;146(2):111-8. (Pubitemid 29474202)
75. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend 2000;58(1-2):143-52.
76. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being. JAMA 1998;280(2):147-51.
77. Morley-Forster PK, Clark AJ, Speechley M, Moulin DE. Attitudes toward opioid use for chronic pain: a Canadian physician survey. Pain Res Manag 2003;8:189-94. (Pubitemid 43020581)
78. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Hamilton, ON: McMaster University; 2010. Available from: http://nationalpaincentre.mcmaster.ca/opioid/ cgop-a00-execu tive-summary.html. Accessed 2011 Nov 17.
79. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998;25(1):139-51. (Pubitemid 28141705)
80. Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126(2):170-5. Epub 2005 Oct 23.
81. Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008;(2):CD006318.
82. Kakko J, Heiling M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008;96(1-2):69-78. Epub 2008 Mar 19.
83. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, et al. Neonatal abstinence syndrome after methadone and buprenorphine exposure. N Engl J Med 2010;363(24):2320-31.
84. Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics 2008;121(4):e782-6.